Titlebook: Early Indicators Early Treatments Neuroprotection in Multiple Sclerosis; Otto R. Hommes,Giancarlo Comi Book 2004 Springer-Verlag Italia 20

Surgeon

Neuroprotective Treatment in Primary Progressive Multiple Sclerosis: a Phase I/II Study with Riluzois might be explained by observations, especially from magnetic resonance imaging (MRI) studies, that the correlation of inflammation with disease progression and development of disability is poor [1].

水獭

Early Treatment of Progression in Multiple Sclerosis,at axonal damage occurs early during RRMS. Disease progression thus develops well in advance of clinical progression and remains subclinical because, due to compensatory mechanisms, impairment does not interfere with daily living activities at that stage.

Clinch

Soluble VCAM-1 Release Indicates Inflammatory Blood-Brain Barrier Pathology and Further Modulates Ain barrier (BBB) during inflammatory central nervous system (CNS) diseases [1]. Adhesion molecules can be induced by proinflammatory cytokines, like tumor necrosis factor-a (TNF-α), on various cell types, e.g., endothelial cells, macrophages, and lymphocytes [2].

Aspiration

gen for autoreactive antibodies might be the central nervous system (CNS) specific myelin oligodendrocyte glycoprotein (MOG), which is exclusively localized on the surface of myelin sheaths and oligodendrocytes.

贪婪地吃

滋养

过分自信

巧思

Inflammation, Demyelination, and Axonal Degeneration: Three Aspects of the Pathogenesis of Multiple relapse, for instance, or the transition from relapsing-remitting disease to progressive accumulation of disability. Here, we report observation from the close study of a small number of patients treated with an experimental agent, Campath-1H, that cast some light on these issues.

Fortuitous

Genetic Regulation of Nerve Cell Death/Glial Activation and Protective Effects of Myelin Basic Prot to ten genes theoretically having a major impact on disease susceptibility [1-3]. This is supported by epidemiological data demonstrating a considerable lowering of concordance rates from monozygotic to dizygotic twins [4]. It has been known for approximately 30 years that certain haplotypes of the

改良

Neuroprotective Treatment in Primary Progressive Multiple Sclerosis: a Phase I/II Study with Riluzoomponent of the disease. Their main clinical impact is on relapses whereas an effect on permanent disability so far has been less well established. This might be explained by observations, especially from magnetic resonance imaging (MRI) studies, that the correlation of inflammation with disease pro